MedTrace Logo

A Study Comparing Propranolol and Amantadine for Reducing Tremors in People With Parkinson's Disease

NCT07113015 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2025-08-08

No results posted yet for this study

Summary

Parkinson's disease is a common brain disorder in older adults that causes tremors (shaking), stiffness, and problems with movement. Among these symptoms, tremors-especially those that occur at rest-can be distressing and interfere with daily life. This study aims to compare two commonly used medications, propranolol and amantadine, to determine which one is more effective and safer in reducing tremors in people with Parkinson's disease.

This clinical trial was conducted with 220 adults aged 50 to 80 years who had a confirmed diagnosis of Parkinson's disease and noticeable resting tremors. Participants were randomly assigned to receive either propranolol or amantadine for 12 weeks, while continuing their usual Parkinson's medications. Tremor severity was measured using a standard scoring tool known as the Unified Parkinson's Disease Rating Scale (UPDRS). Quality of life and side effects were also closely monitored.

The hypothesis is that propranolol would be more effective in reducing tremor severity than amantadine, though it might be associated with more side effects. Both medications were given in tablet form, twice daily, and doses were adjusted based on patient response and tolerance.

At the end of the study, both groups showed improvement, but propranolol was more effective at reducing tremors. However, it caused more side effects such as tiredness and dizziness. Quality of life improved in both groups with no major difference between them. This study may help doctors decide which medication is more suitable for treating tremors in Parkinson's disease, based on the patient's health status and side effect tolerance.

Conditions

  • Parkinson Disease (PD)
  • Tremor

Interventions

DRUG

propranolol

40 mg orally twice daily, titrated up to a maximum of 80 mg/day.

DRUG

Amantadine

100 mg orally twice daily, titrated up to a maximum of 200 mg/day.

Sponsors & Collaborators

  • Multan Medical And Dental College

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-05
Primary Completion
2024-12-02
Completion
2024-12-02

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07113015 on ClinicalTrials.gov